Last updated: 2026-09-17 07:31:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Alvotech (ALVO) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $5.11, with a market capitalization of $1.79B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.94 to $9.25. This page covers its latest market performance, valuation, price trends and company information.
$1.79B | |
$5.40 | |
$18.00 | |
$2.94 | |
$5.02 | |
3.47M | |
908.15K | |
-- | |
$9.25 | |
$2.94 | |
-- | |
-- |
Alvotech (ALVO) last closed at $5.02 as of 2026-09-16 23:58:00, unchanged from the previous close of $5.02.
During the latest regular trading session, ALVO traded between $2.94 and $18.00, with a volume of 3.47M shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Alvotech (ALVO) moved from $5.19 to $5.11, representing a decline of 1.50% ($0.08).
The stock traded between $4.90 and $5.53 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 1.08 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 34.4%
ALVO is currently trading at $5.11, placing it 34.4% of the way from its 52-week low of $2.94 to its 52-week high of $9.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
| Employees | 1460 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Alvotech (ALVO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.